Evidence map›Paper›PMID 39523996›Full record

ArticleAlimentary pharmacology & therapeutics2025

Factors Associated With Motivation to Reduce Alcohol Use Among Patients With Chronic Liver Disease.

Derek D Satre, Dhweeja Dasarathy, Steven L Batki, Michael J Ostacher, Hannah R Snyder, William Hua, Priti Parekh, Amy M Shui, Ramsey Cheung, Alexander Monto and 8 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05191446 (Impact of the Coronavirus 2019), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05191446 naactive not recruitingnot on this map

Impact of the Coronavirus 2019 (COVID-19) Pandemic on Patient Outcomes, Telehealth Care Delivery, and Treatment for Unhealthy Alcohol Use in Vulnerable Patients With Advanced Liver Disease Across Two Healthcare Systems

TypeinterventionalSponsorUniversity of California, San FranciscoRan2022 to 2026Enrolled180ConditionsLiver Diseases, Alcohol Use DisorderArmsStepped alcohol intervention (SAT) to reduce unhealthy alcohol use, Usual Care (UC)
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Derek D SatreDepartment of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, California, USA.ORCID https://orcid.org/0000-0002-4228-1504
Dhweeja DasarathyVanderbilt School of Medicine, Nashville, Tennessee, USA.
Steven L BatkiDepartment of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, California, USA.
Michael J OstacherDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, USA.
Hannah R SnyderDepartment of Family and Community Medicine, University of California, San Francisco, California, USA.
William HuaDepartment of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California, San Francisco, California, USA.
Priti ParekhDivision of Gastroenterology and Hepatology, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.
Amy M ShuiDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Ramsey CheungDivision of Gastroenterology and Hepatology, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.
Alexander MontoDivision of Gastroenterology and Hepatology, Veterans Affairs San Francisco Health Care System, San Francisco, California, USA.
Robert J WongDivision of Gastroenterology and Hepatology, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.
Jennifer Y ChenDivision of Gastroenterology and Hepatology, Zuckerberg San Francisco General, San Francisco, California, USA.
Meimei LiaoDivision of Gastroenterology and Hepatology, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.
Michele TanaDivision of Gastroenterology and Hepatology, Zuckerberg San Francisco General, San Francisco, California, USA.
Po-Hung ChenDivision of Gastroenterology & Hepatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Christina G HaightDivision of Gastroenterology and Hepatology, Veterans Affairs San Francisco Health Care System, San Francisco, California, USA.
Taylor FakadejDivision of Gastroenterology and Hepatology, Zuckerberg San Francisco General, San Francisco, California, USA.
Mandana KhaliliDivision of Gastroenterology and Hepatology, Zuckerberg San Francisco General, San Francisco, California, USA.ORCID https://orcid.org/0000-0001-9178-9139

Funding

UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
Impact of the COVID-19 pandemic on patient outcomes, telehealth care delivery, and treatment for unhealthy alcohol use in vulnerable patients with advanced liver disease across two healthcare systemsR01AA029312 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KHALILI, MANDANA, SATRE, DEREK D · 2021 to 2025
$3.5M
Mentoring Multidisciplinary Patient-Oriented Research in Viral HepatitisK24AA022523 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KHALILI, MANDANA · 2013 to 2023
$1.9M
Mentoring alcohol use intervention research in HIV health care settingsK24AA025703 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Derek D Satre · 2018 to 2026
$1.8M
Candidate Selection for Liver Transplantation in Patients with Alcohol-related Liver DiseaseK23AA028297 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI CHEN, PO-HUNG (VICTOR) · 2020 to 2024
$991k
NIAAA NIH HHS K23 AA028297NIAAA NIH HHS K24 AA022523NIAAA NIH HHS K24AA022523NIAAA NIH HHS K24 AA025703NIAAA NIH HHS K24AA025703NIAAA NIH HHS R01 AA029312NIAAA NIH HHS R01AA029312NIDDK NIH HHS P30 DK026743The UCSF Dolby Family Center for Mood Disorders
6 · The paper itself

Abstract

BACKGROUND AND

aimsAlcohol use is prevalent among hepatology clinic patients with chronic liver disease (CLD). We explored factors associated with the importance and confidence dimensions of motivation to reduce drinking.

methodsParticipants (N = 121) with unhealthy alcohol use (i.e., over NIH guidelines) receiving care in hepatology clinics from a safety-net hospital (SN, N = 54) and two Veterans Affairs Healthcare Systems (VA, N = 67) were enrolled in an alcohol intervention trial from March 2022 through October 2023. Baseline assessments included Generalised Anxiety Disorder (GAD-7), Patient Health Questionnaire (PHQ-8), Alcohol Use Disorders Identification Test (AUDIT), COVID-19 stress; and measures of importance and confidence to decrease alcohol use (readiness rulers, scales of 1-10). Liver disease aetiology and severity were extracted from electronic health records. We performed multivariable linear regression models with forward selection to assess pre-specified variables' associations with importance and confidence.

resultsThe sample was 84% male, 40% Latino, 31% White, 18% Black and 11% other races; median age was 61 years. Median (Q1-Q3) AUDIT score was 16 (12-24), importance was 9 (6-10) and confidence was 8 (5-9). On multivariable analysis, VA site (vs. SN) participants had a 0.97-point lower importance score (p = 0.02); higher symptoms of depression (PHQ-8 score ≥ 10 vs. < 10) and AUDIT scores (for each point increase) were associated with higher importance score (estimates 1.2 and 0.08, p < 0.05, respectively). Liver disease aetiology and severity were not significantly associated with outcomes.

conclusionsDepression, alcohol problem severity and treatment site may influence motivation to reduce alcohol use and could inform future hepatology-based interventions.

Indexed as

COVID-19Liver DiseasesMotivationAdultAgedAlcohol DrinkingAlcoholismChronic DiseaseFemaleHumansMaleMiddle AgedUnited Statesalcoholalcohol‐associated liver diseasecirrhosisCOVID‐19depressionmetabolic‐associated steatohepatitismetabolic dysfunction‐associated steatotic liver disease

Identifiers

PMID39523996
PMCPMC11710982

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.